Aldose Reductase
From Proteopedia
(Difference between revisions)
| Line 33: | Line 33: | ||
**[[2bgq]] – bAldR - barley<br /> | **[[2bgq]] – bAldR - barley<br /> | ||
**[[2bgs]] - bAldR+NADP<br /> | **[[2bgs]] - bAldR+NADP<br /> | ||
| + | **[[5jh1]] – maAldR – maize<br /> | ||
*Aldose Reductase+inhibitors | *Aldose Reductase+inhibitors | ||
| - | **[[3ghr]], [[3ghs]], [[3ght]], [[3ghu]], [[2r24]], [[2pzn]], [[3g5e]], [[2qxw]], [[2iki]], [[2i16]], [[2i17]], [[1t40]], [[1t41]], [[1us0]], [[1el3]], [[3t42]] - hAldR +NADP+IDD inhibitors<br /> | + | **[[3ghr]], [[3ghs]], [[3ght]], [[3ghu]], [[2r24]], [[2pzn]], [[3g5e]], [[2qxw]], [[2iki]], [[2i16]], [[2i17]], [[1t40]], [[1t41]], [[1us0]], [[1el3]], [[3t42]], [[4ys1]], [[4rpq]], [[4qr6]], [[4qbx]], [[4q7b]], [[2pev]], [[2pf8]], [[2pfh]], [[4puw]], [[4puu]] - hAldR +NADP+IDD inhibitors<br /> |
| - | **[[3onb]], [[3onc]] – hAldR (mutant) +NADP+IDD inhibitor<br /> | + | **[[3onb]], [[3onc]], [[2pdk]], [[1az1]] – hAldR (mutant) +NADP+IDD inhibitor<br /> |
**[[3u2c]] - hAldR +NADP+ NSAID inhibitor<br /> | **[[3u2c]] - hAldR +NADP+ NSAID inhibitor<br /> | ||
**[[3bcj]], [[1x97]], [[1x98]], [[1pwm]], [[1ef3]], [[2pd5]], [[2dux]], [[2duz]], [[2dv0]], [[2fz8]], [[2fz9]], [[2hv5]], [[2hvn]], [[2hvo]], [[1mar]], [[2fzb]], [[2fzd]], [[1z3n]], [[1pwl]], [[1iei]], [[4jir]] - hAldR+NADP+inhibitor for diabetic treatment<br /> | **[[3bcj]], [[1x97]], [[1x98]], [[1pwm]], [[1ef3]], [[2pd5]], [[2dux]], [[2duz]], [[2dv0]], [[2fz8]], [[2fz9]], [[2hv5]], [[2hvn]], [[2hvo]], [[1mar]], [[2fzb]], [[2fzd]], [[1z3n]], [[1pwl]], [[1iei]], [[4jir]] - hAldR+NADP+inhibitor for diabetic treatment<br /> | ||
**[[1z89]], [[1z8a]] - hAldR+NADP+sulfonyl-pyridazinone<br /> | **[[1z89]], [[1z8a]] - hAldR+NADP+sulfonyl-pyridazinone<br /> | ||
| - | **[[2pdg]], [[2pdh]] - hAldR+NADP+uracil inhibitor<br /> | + | **[[5ha7]] – hAldR (mutant) +NADP+pyrimidine inhibitor<br /> |
| + | **[[4yu1]], [[4prt]], [[4prr]], [[4pr4]], [[4nkc]] – hAldR +NADP+ diphenyl inhibitor<br /> | ||
| + | **[[2pdg]], [[2pdh]], [[4xzi]], [[4xzh]] - hAldR+NADP+uracil inhibitor<br /> | ||
**[[1x96]], [[2acs]], [[2acu]] - hAldR+NADP+citrate<br /> | **[[1x96]], [[2acs]], [[2acu]] - hAldR+NADP+citrate<br /> | ||
**[[2acq]] - hAldR +NADP+glucose phosphate<br /> | **[[2acq]] - hAldR +NADP+glucose phosphate<br /> | ||
| Line 49: | Line 52: | ||
**[[2nvc]], [[2nvd]] - hAldR+NADP+isothiazole inhibitor<br /> | **[[2nvc]], [[2nvd]] - hAldR+NADP+isothiazole inhibitor<br /> | ||
**[[3p2v]] - hAldR+NADP+ benzothiazepine inhibitor<br /> | **[[3p2v]] - hAldR+NADP+ benzothiazepine inhibitor<br /> | ||
| - | **[[2pev]], [[2pf8]], [[2pfh]] - hAldR+NADP+IDD inhibitor+ fidarestat<br /> | ||
**[[2ipw]], [[2iq0]], [[2iqd]], [[2isf]], [[2ine]], [[2inz]], [[2is7]] - hAldR+NADP+ acid<br /> | **[[2ipw]], [[2iq0]], [[2iqd]], [[2isf]], [[2ine]], [[2inz]], [[2is7]] - hAldR+NADP+ acid<br /> | ||
**[[2f2k]] - hAldR+NADP+DEG<br /> | **[[2f2k]] - hAldR+NADP+DEG<br /> | ||
**[[2pdn]], [[2pdq]] – hAldR (mutant)+NADP+uracil inhibitor<br /> | **[[2pdn]], [[2pdq]] – hAldR (mutant)+NADP+uracil inhibitor<br /> | ||
**[[2pdb]], [[2pdf]], [[2pdi]], [[2pdm]], [[2pdx]], [[3len]], [[3m0i]], [[3mb9]], [[2pd9]], [[2pdw]], [[2pdy]], [[2agt]], [[2pdl]] – hAldR (mutant)+NADP+inhibitor for diabetic treatment<br /> | **[[2pdb]], [[2pdf]], [[2pdi]], [[2pdm]], [[2pdx]], [[3len]], [[3m0i]], [[3mb9]], [[2pd9]], [[2pdw]], [[2pdy]], [[2agt]], [[2pdl]] – hAldR (mutant)+NADP+inhibitor for diabetic treatment<br /> | ||
| - | **[[2pdk]] - hAldR (mutant)+NADP+sorbinil<br /> | ||
| - | **[[1az1]] – hAldR (mutant)+NADP+alrestatin<br /> | ||
**[[1az2]] - hAldR (mutant)+NADP+citrate<br /> | **[[1az2]] - hAldR (mutant)+NADP+citrate<br /> | ||
**[[3lbo]], [[3ld5]], [[3lql]], [[3lz5]], [[2pdc]], [[3lep]], [[3lqg]], [[3lz3]], [[3m4h]], [[2pdj]], [[2pdp]], [[2pdu]], [[3m64]], [[3mc5]] - hAldR (mutant)+IDD inhibitors<br /> | **[[3lbo]], [[3ld5]], [[3lql]], [[3lz5]], [[2pdc]], [[3lep]], [[3lqg]], [[3lz3]], [[3m4h]], [[2pdj]], [[2pdp]], [[2pdu]], [[3m64]], [[3mc5]] - hAldR (mutant)+IDD inhibitors<br /> | ||
| Line 61: | Line 61: | ||
**[[3rx2]], [[3rx3]], [[3rx4]], [[3s3g]] - hAldR+NADP+ sulindac inhibitor<br /> | **[[3rx2]], [[3rx3]], [[3rx4]], [[3s3g]] - hAldR+NADP+ sulindac inhibitor<br /> | ||
**[[4igs]] - hAldR+NADP+ polyfluorinated inhibitor<br /> | **[[4igs]] - hAldR+NADP+ polyfluorinated inhibitor<br /> | ||
| - | **[[4lau]], [[4laz]], [[4lb3]], [[4lb4]], [[4lbr]], [[4lbs]] - hAldR+NADP+ carbamoyl inhibitor<br /> | + | **[[4lau]], [[4laz]], [[4lb3]], [[4lb4]], [[4lbr]], [[4lbs]], [[4qxi]] - hAldR+NADP+ carbamoyl inhibitor<br /> |
| + | **[[4qx4]] - hAldR+NADP+ mercaptotriazinoindole inhibitor<br /> | ||
**[[3fx4]] – pAldR+NADP+thiazolidine derivative <br /> | **[[3fx4]] – pAldR+NADP+thiazolidine derivative <br /> | ||
| - | **[[ | + | **[[1eko]], [[1ah0]], [[3h4g]], [[1ah3]], [[1ae4]] - pAldR+NADP+IDD inhibitor<br /> |
| - | + | ||
| - | + | ||
| - | + | ||
**[[2vdg]] – bAldR+NADP+butanol <br /> | **[[2vdg]] – bAldR+NADP+butanol <br /> | ||
| + | **[[5jh2]] – maAldR + adenosine diphosphate <br /> | ||
}} | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 09:20, 1 March 2017
| |||||||||||
3D Structures of Aldose Reductase
Updated on 01-March-2017
References
- ↑ Rondeau JM, Tete-Favier F, Podjarny A, Reymann JM, Barth P, Biellmann JF, Moras D. Novel NADPH-binding domain revealed by the crystal structure of aldose reductase. Nature. 1992 Jan 30;355(6359):469-72. PMID:1734286 doi:http://dx.doi.org/10.1038/355469a0
- ↑ Wilson DK, Bohren KM, Gabbay KH, Quiocho FA. An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science. 1992 Jul 3;257(5066):81-4. PMID:1621098
